Amgen’s Stelara Biosimilar Produces Positive Phase III Results

Firm’s ABP 654 Ustekinumab Candidate Is Also Being Lined Up For Interchangeability

 
• By David Wallace
  
Amgen offices at Cambridge Science Park
Amgen has announced progress on its ustekinumab candidate • Source: Alamy

More from Biosimilars

More from Products